Current Cardiology Reports

, 21:93 | Cite as

Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment

  • Gregory L. HundemerEmail author
Hypertension (DS Geller and DL Cohen, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hypertension


Purpose of Review

Primary aldosteronism (PA) is a common form of hypertension characterized by autonomous aldosterone secretion from one or both adrenal glands. The purpose of this review is to synthesize recent research findings regarding cardiovascular disease risk in PA both pre- and post-targeted therapy.

Recent Findings

Previously considered a rare disease, recent prevalence studies demonstrate that PA is actually a very common, yet vastly under-diagnosed, etiology of hypertension. Prior to targeted therapy, PA is associated with substantially higher rates of cardiovascular disease compared with essential hypertension. Surgical adrenalectomy is highly effective in curing or improving hypertension as well as mitigating cardiovascular disease risk in patients with unilateral PA. For the remainder of PA patients, MR antagonists are recommended; however, several recent studies have brought into question their effectiveness in improving cardiovascular outcomes.


PA is a common cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Future studies are needed to enhance the clinical approach to both identification and treatment of patients with PA to optimize long-term cardiovascular outcomes.


Primary aldosteronism Primary hyperaldosteronism Conn’s syndrome Mineralocorticoid receptor antagonist Cardiovascular disease Atrial fibrillation 


Compliance with Ethical Standards

Conflict of Interest

Gregory L. Hundemer declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Barrett KV, McCurley AT, Jaffe IZ. Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation. Clin Exp Pharmacol Physiol. 2013;40(12):902–9.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120(6):893–901.PubMedGoogle Scholar
  3. 3.
    Diaz-Otero JM, Fisher C, Downs K, Moss ME, Jaffe IZ, Jackson WF, et al. Endothelial mineralocorticoid receptor mediates parenchymal arteriole and posterior cerebral artery remodeling during angiotensin II-induced hypertension. Hypertension. 2017;70(6):1113–21.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Kim SK, McCurley AT, DuPont JJ, Aronovitz M, Moss ME, Stillman IE, et al. Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging. Hypertension. 2018;71(4):609–21.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension. 2002;39(2 Pt 2):614–8.PubMedGoogle Scholar
  6. 6.
    McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18(9):1429–33.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Mueller KB, Bender SB, Hong K, Yang Y, Aronovitz M, Jaisser F, et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension. 2015;66(5):988–97.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.PubMedGoogle Scholar
  9. 9.
    Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141(10):3871–8.PubMedGoogle Scholar
  10. 10.
    Tesch GH, Young MJ. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol. 2017;8:313.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350(2):266–72.PubMedGoogle Scholar
  12. 12.
    Jansen PM, Boomsma F, van den Meiracker AH, Dutch AI. Aldosterone-to-renin ratio as a screening test for primary aldosteronism—the Dutch ARRAT Study. Neth J Med. 2008;66(5):220–8.PubMedGoogle Scholar
  13. 13.
    Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101(7):2826–35.PubMedGoogle Scholar
  14. 14.
    Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85(8):2854–9.PubMedGoogle Scholar
  15. 15.
    •• Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811–20 Large well-designed study assessing the prevalence of primary aldosteronism in the hypertensive population.PubMedGoogle Scholar
  16. 16.
    Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161–5.PubMedGoogle Scholar
  17. 17.
    Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.PubMedGoogle Scholar
  18. 18.
    Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202.PubMedGoogle Scholar
  19. 19.
    Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172(5):R191–203.PubMedGoogle Scholar
  20. 20.
    Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–300.PubMedGoogle Scholar
  21. 21.
    Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892–6.PubMedGoogle Scholar
  22. 22.
    Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18(6):805–12.PubMedGoogle Scholar
  24. 24.
    •• Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916 Most widely accepted guidelines for the evaluation and management of primary aldosteronism.PubMedGoogle Scholar
  25. 25.
    Ruhle BC, White MG, Alsafran S, Kaplan EL, Angelos P, Grogan RH. Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives. Surgery. 2019;165(1):221–7.PubMedGoogle Scholar
  26. 26.
    Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab. 2016;101(11):3989–96.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013;98(4):1409–16.PubMedGoogle Scholar
  28. 28.
    Maiolino G, Calo LA, Rossi GP. The time has come for systematic screening for primary aldosteronism in all hypertensives. J Am Coll Cardiol. 2017;69(14):1821–3.PubMedGoogle Scholar
  29. 29.
    Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39(6):1057–88.PubMedGoogle Scholar
  30. 30.
    Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol. 2007;66(5):607–18.Google Scholar
  31. 31.
    Stowasser M, Gordon RD. Primary aldosteronism—careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217(1–2):33–9.PubMedGoogle Scholar
  32. 32.
    Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126–48.PubMedGoogle Scholar
  33. 33.
    Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151(5):329–37.PubMedGoogle Scholar
  34. 34.
    Lim V, Guo Q, Grant CS, Thompson GB, Richards ML, Farley DR, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab. 2014;99(8):2712–9.PubMedGoogle Scholar
  35. 35.
    Nanba AT, Nanba K, Byrd JB, Shields JJ, Giordano TJ, Miller BS, et al. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol. 2017;87(6):665–72.Google Scholar
  36. 36.
    •• Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689–99 Large international study assessing outcomes in unilateral primary aldosteronism following surgical adrenalectomy.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–35.PubMedGoogle Scholar
  38. 38.
    Kupers EM, Amar L, Raynaud A, Plouin PF, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012;97(10):3530–7.PubMedGoogle Scholar
  39. 39.
    Riester A, Fischer E, Degenhart C, Reiser MF, Bidlingmaier M, Beuschlein F, et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab. 2014;99(6):E1035–9.PubMedGoogle Scholar
  40. 40.
    Rossi GP. Update in adrenal venous sampling for primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2018;25(3):160–71.PubMedGoogle Scholar
  41. 41.
    Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60.PubMedGoogle Scholar
  42. 42.
    Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006;19(1):13–8.PubMedGoogle Scholar
  43. 43.
    Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40(1):23–7.PubMedGoogle Scholar
  44. 44.
    Cesari M, Letizia C, Angeli P, Sciomer S, Rosi S, Rossi GP. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study. Circ Cardiovasc Imaging. 2016;9(6).Google Scholar
  45. 45.
    Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation. 1997;95(6):1471–8.PubMedGoogle Scholar
  46. 46.
    Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27(5):1039–45.PubMedGoogle Scholar
  47. 47.
    Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–6.PubMedGoogle Scholar
  48. 48.
    Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070–6.PubMedGoogle Scholar
  49. 49.
    Yoshihara F, Nishikimi T, Yoshitomi Y, Nakasone I, Abe H, Matsuoka H, et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens. 1996;9(6):523–8.PubMedGoogle Scholar
  50. 50.
    Chen ZW, Huang KC, Lee JK, Lin LC, Chen CW, Chang YY, et al. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. J Hypertens. 2018;36(2):353–60.PubMedGoogle Scholar
  51. 51.
    Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80–5.PubMedGoogle Scholar
  52. 52.
    •• Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51–9 Large retrospective study comparing cardiovascular outcomes in primary aldosteronism post-targeted therapy (surgical adrenalectomy or mineralocorticoid receptor antagonists) versus comparable patients with essential hypertension. Additionally, this study suggests that renin may be an informative biomarker to guide treatment in primary aldosteronism.PubMedGoogle Scholar
  53. 53.
    Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8.PubMedGoogle Scholar
  54. 54.
    •• Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50 Recent meta-analysis on cardiovascular outcomes in primary aldosteronism prior to targeted therapy versus essential hypertension.PubMedGoogle Scholar
  55. 55.
    Murata M, Kitamura T, Tamada D, Mukai K, Kurebayashi S, Yamamoto T, et al. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J Hypertens. 2017;35(5):1079–85.PubMedGoogle Scholar
  56. 56.
    Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Investig. 1995;18(5):370–3.Google Scholar
  57. 57.
    Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schafers HJ, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289(10):6656–68.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33(16):2098–108.PubMedGoogle Scholar
  59. 59.
    Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598–603.PubMedGoogle Scholar
  60. 60.
    • Takemoto Y, Ramirez RJ, Kaur K, Salvador-Montanes O, Ponce-Balbuena D, Ramos-Mondragon R, et al. Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J Am Coll Cardiol. 2017;70(23):2893–905 Animal model demonstrating that blockade of the mineralocorticoid receptor can prevent atrial fibrillation.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, Wu CK, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol. 2010;55(8):758–70.PubMedGoogle Scholar
  62. 62.
    Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–33.PubMedGoogle Scholar
  63. 63.
    Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62–9.PubMedGoogle Scholar
  64. 64.
    •• Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension. 2018;71(4):585–91 Observational study showing that surgical adrenalectomy in primary aldosteronism is effective at reducing incident atrial fibrillation whereas patients treated with mineralocorticoid receptor antagonists remain at higher risk.PubMedGoogle Scholar
  65. 65.
    •• Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3(8):768–74 Observational study showing that greater mineralocorticoid receptor blockade, as reflected by a rise in renin, associates with a lower risk of incident atrial fibrillation.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.PubMedGoogle Scholar
  67. 67.
    Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–9.PubMedGoogle Scholar
  68. 68.
    Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9(2):104–12.PubMedGoogle Scholar
  69. 69.
    Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27(11):2192–200.PubMedGoogle Scholar
  70. 70.
    Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension. 2012;60(3):618–24.PubMedGoogle Scholar
  71. 71.
    Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–9.PubMedGoogle Scholar
  72. 72.
    Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–14.PubMedGoogle Scholar
  73. 73.
    Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413–20.PubMedGoogle Scholar
  74. 74.
    Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–11.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Chen W, Li F, He C, Zhu Y, Tan W. Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis. Ir J Med Sci. 2014;183(2):283–91.PubMedGoogle Scholar
  76. 76.
    Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9.PubMedGoogle Scholar
  77. 77.
    Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol. 2015;173(5):665–75.PubMedGoogle Scholar
  78. 78.
    Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, et al. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens. 2017;35(8):1698–708.PubMedGoogle Scholar
  79. 79.
    Adolf C, Kohler A, Franke A, Lang K, Riester A, Low A, et al. Cortisol excess in patients with primary aldosteronism impacts left ventricular hypertrophy. J Clin Endocrinol Metab. 2018;103(12):4543–52.PubMedGoogle Scholar
  80. 80.
    • Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight. 2017;2(8). Metabolomic study showing that cortisol co-secretion is common in primary aldosteronism which may explain the high co-occurrence of diabetes mellitus. Google Scholar
  81. 81.
    Beuschlein F, Reincke M, Arlt W. The impact of Connshing’s syndrome—mild cortisol excess in primary aldosteronism drives diabetes risk. J Hypertens. 2017;35(12):2548.PubMedGoogle Scholar
  82. 82.
    Calhoun DA. Medical versus surgical treatment of primary aldosteronism. Hypertension. 2018;71(4):566–8.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Duncan JL, 3rd, Fuhrman GM, Bolton JS, Bowen JD, Richardson WS. Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism. Am Surg 2000;66(10):932–935; discussion 5-6.Google Scholar
  84. 84.
    Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol. 2003;169(1):32–5.PubMedGoogle Scholar
  85. 85.
    Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg. 2002;68(3):253–6 discussion 6-7.PubMedGoogle Scholar
  86. 86.
    Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994;121(11):877–85.PubMedGoogle Scholar
  87. 87.
    Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol. 2003;29(5):467–74.PubMedGoogle Scholar
  88. 88.
    Lo CY, Tam PC, Kung AW, Lam KS, Wong J. Primary aldosteronism. Results of surgical treatment. Ann Surg. 1996;224(2):125–30.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg. 2005;29(2):155–9.PubMedGoogle Scholar
  90. 90.
    Stowasser M, Klemm SA, Tunny TJ, Storie WJ, Rutherford JC, Gordon RD. Response to unilateral adrenalectomy for aldosterone-producing adenoma: effect of potassium levels and angiotensin responsiveness. Clin Exp Pharmacol Physiol. 1994;21(4):319–22.PubMedGoogle Scholar
  91. 91.
    Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010;95(3):1360–4.PubMedGoogle Scholar
  92. 92.
    Burrello J, Burrello A, Stowasser M, Nishikawa T, Quinkler M, Prejbisz A, et al. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg. 2019.Google Scholar
  93. 93.
    Vorselaars W, Nell S, Postma EL, Zarnegar R, Drake FT, Duh QY, et al. Clinical outcomes after unilateral adrenalectomy for primary aldosteronism. JAMA Surg. 2019:e185842.PubMedGoogle Scholar
  94. 94.
    Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J Clin Endocrinol Metab. 2018;103(1):16–24.PubMedGoogle Scholar
  95. 95.
    Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, et al. Long term outcome of aldosteronism after target treatments. Sci Rep. 2016;6:32103.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–90.PubMedGoogle Scholar
  97. 97.
    Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658–66.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Nephrology, Ottawa Hospital Research InstituteUniversity of OttawaOttawaCanada

Personalised recommendations